This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Fate Therapeutics’s 8K filing here.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.
Further Reading
- Five stocks we like better than Fate Therapeutics
- Technology Stocks Explained: Here’s What to Know About Tech
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Penny Stocks Ready to Break Out in 2025
- 3 Fintech Stocks With Good 2021 Prospects
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
